

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/137044 A1

(51) International Patent Classification:

C07K 16/00 (2006.01) G01N 33/86 (2006.01)
G01N 33/53 (2006.01)

(21) International Application Number:

PCT/US2024/060680

(22) International Filing Date:

18 December 2024 (18.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/611,692 18 December 2023 (18.12.2023) US

(71) Applicants: AMUNIX PHARMACEUTICALS, INC.

[US/US]; 500 Ellis Street, Mountain view, California 94003 (US). BIOVERATIV THERAPEUTICS INC. [US/US]; 225 Second Avenue, Waltham, Massachusetts 02451 (US).

(72) Inventors: CAMPBELL, Andrew; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). SETH CHHABRA, Ekta; c/o Sanofi, Patent

Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). WILLEMZE, Annemieke; c/o Sanofi B.V., Paasheuvelweg 25, 1105 BP Amsterdam (NL).

(74) Agent: VELEMA, James H. et al.; LATHROP GPM LLP,

28 State Street, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,


AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: ANTIBODIES AND ASSAYS FOR DETERMINING CLOTTING FACTOR VIII ACTIVITY

FIG. 1



(57) Abstract: The present disclosure provides anti-ELNN antibodies, as well as methods for assaying the level of Clotting Factor VIII (FVIII) activity level of certain chimeric proteins. Methods provided include methods for determining the level of FVIII activity in the blood or plasma of a human subject who has Willebrand disease (WVD) and to whom an ELNN- and/or VWF fragment-containing chimeric protein such as efanoctocog alfa has been administered.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*